Imatinib Mesylate (Gleevec(TM))-induced Lichenoid Drug Eruption Improved by Tentative Dose-reduction and Topical Steroid / 대한피부과학회지
Korean Journal of Dermatology
; : 155-158, 2011.
Article
en Ko
| WPRIM
| ID: wpr-16200
Biblioteca responsable:
WPRO
ABSTRACT
Imatinib mesylate (Gleevec(TM)) is an oral anticancer drug. It works as a selective and competitive inhibitor of tyrosine kinases such as bcr-abl protein, c-kit, and platelet-derived growth factor receptors (PDGFR). Gleevec(TM) is a first-line therapeutic agent for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors, but causes various adverse cutaneous reactions. We herein report on a case of lichenoid drug eruption induced by Gleevec(TM) in a patient with a malignant gastrointestinal stromal tumor.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Fosfotransferasas
/
Piperazinas
/
Pirimidinas
/
Tirosina
/
Benzamidas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Receptores del Factor de Crecimiento Derivado de Plaquetas
/
Erupciones por Medicamentos
/
Mesilatos
/
Tumores del Estroma Gastrointestinal
Límite:
Humans
Idioma:
Ko
Revista:
Korean Journal of Dermatology
Año:
2011
Tipo del documento:
Article